Behavior of tetrahydrolipstatin in biological model membranes and emulsions

Journal of Lipid Research

Volumn 38, Issue 8, 1997, Pages 1544-1552

  Ko, John ^a   Small, Donald M ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbon 13 NMR; Fat absorption lipase inhibitors; Lipid bilayers; Lipstatin; Microemulsions; Pancreatic lipase

Indexed keywords

ENZYME INHIBITOR; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE;

ARTICLE; BEHAVIOR; BILAYER MEMBRANE; BIOLOGICAL MODEL; CARBON NUCLEAR MAGNETIC RESONANCE; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME SUBSTRATE; HYDROPHOBICITY; LIPID BILAYER; MICROEMULSION; NONHUMAN; OBESITY; PRIORITY JOURNAL;

EMULSIONS; ENZYME INHIBITORS; LACTONES; LIPASE; LIPOSOMES; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANES, ARTIFICIAL; MODELS, MOLECULAR; SOLVENTS;

EID: 0030868517     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Weibel, E. K., P. Hadváry, E. Hochuli, E. Kupfer, and H. Lengsfeld. 1987. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J. Antibiot. 40: 1081-1085.
2. Hochuli, E., E. Kupfer, R. Maurer, W. Meister, Y. Mercadal, and K. Schmidt. 1987. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. II. Chemistry and structure elucidation. J. Antibiot. 40: 1086-1091.
3. Carey, M. C., D. M. Small, and C. M. Bliss. 1983. Lipid digestion and absorption. Annu. Rev. Physiol. 45: 651-677.
4. Hadváry, P., H. Lengsfeld, and H. Wolfer. 1988. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem. J. 256: 357-361.
5. Borgström, B. 1988. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim. Biophys. Acta. 962: 308-316.
6. Fernandez, E., and B. Borgström. 1989. Effects of tetrahydrolipstatin, a lipase inhibitor, on absorption of fat from the intestine of the rat. Biochim. Biophys. Acta. 1001: 249-255.
7. Hauptman, J. B., F. S. Jeunet, and D. Hartmann. 1992. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am. J. Clin. Nutr. 55: 309S-313S.
8. Hadváry, P., W. Sidler, W. Meister, W. Vetter, and H. Wolfer. 1991. The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J. Biol. Chem. 266: 2021-2027.
9. Lüthi-Peng, Q., H. P. Märki, and P. Hadváry. 1992. Identification of the active-site serine in human pancreatic lipase by chemical modification with tetrahydrolipstatin. FEBS Lett. 299: 111-115.
10. Hogan, S., A. Fleury, P. Hadváry, H. Lengsfeld, M. K. Meier, J. Triscari, and A. C. Sullivan. 1987. Studies on the antiobesity activity of tetrehydrolipstatin, a potent and selective inhibitor of pancreatic lipase. Int. J. Obes. 11 (Suppl. 3): 35-42.
11. Zhi, J., A. T. Mela, R. Guerciolini, J. Chung, J. Kinberg, J. B. Hauptman, and I. H. Patel. 1994. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin. Pharmacol. Ther. 56: 82-85.
12. Zhi, J., A. T. Melia, H. Eggers, J. Raymond, and I. H. Patel. 1995. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J. Clin. Pharmacol. 35: 1103-1108.
13. 13C NMR study. Proc. Natl. Acad. Sci. USA. 78: 6878-6882.
14. Cabral, D. J., J. A. Hamilton, and D. M. Small. 1986. The ionization behavior of bile acids in different aqueous environments. J. Lipid Res. 27: 334-343.
15. Cabral, D. J., D. M. Small, H. S. Lilly, and J. A. Hamilton. 1987. Transbilayer movement of bile acids in model membranes. Biochemistry. 26: 1801-1804.
16. Hamilton, J. A., S. P. Bhamidipati, D. R. Kodali, and D. M. Small. 1991. The interfacial conformation and transbilayer movement of diacylglycerols in phospholipid bilayers. J. Biol. Chem. 266: 1177-1186.